Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 64, Issue 5, 2007, Pages 655-661

  Hoetelmans, Richard M W ^a   Mariën, Kris ^a   De Pauw, Martine ^a   Hill, Andrew ^b   Peeters, Monika ^a   Sekar, Vanitha ^c   De Doncker, Piet ^a   Woodfall, Brian ^a   Lefebvre, Eric ^c  

^a TIBOTEC BVBA   (Belgium)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c Tibotec Inc   (United States)

Author keywords

Darunavir; Interaction; Ritonavir; Tenofovir disoproxil fumarate; TMC114

Indexed keywords

DARUNAVIR; DARUNAVIR PLUS RITONAVIR; PREZISTA; PROTEINASE INHIBITOR; RITONAVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS; LOOSE FECES; LOW DRUG DOSE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION; VIRUS RESISTANCE; VOLUNTEER; WILD TYPE;

ADENINE; ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RITONAVIR; TREATMENT OUTCOME;

EID: 35248848266     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02957.x     Document Type: Article

References (24)

1. De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, Wigerinck P, de Bethune M-P. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005 49 : 2314 21.
2. Prezista™. NDA no. 021976. Available at http://www.fda.gov/cder/ foi/label/2006/021976lbl.pdf Last accessed 15 December 2006.
3. Hoetelmans R, Van der Sandt I, De Pauw M, Struble K, Peeters M, van der Geest R. TMC114, A Next Generation HIV Protease Inhibitor. Pharmacokinetics and Safety Following Oral Administration of Multiple Doses with and without Low Doses of Ritonavir in Healthy Volunteers [549]. Presented at 10th Conference on Retroviruses and Opportunistic Infections, Boston. 2003.
4. Katlama C, Carvalho MTM, Cooper D, De Backer K, Lefebvre E, Pedro R, Rombouts K, Stoehr A, Vangeneugden T, Woehrmann A. TMC114/r Outperforms Investigator-Selected PI (s) in 3-Class-Experienced Patients: Week 24 Primary Efficacy Analysis of POWER 1 (TMC114-C213) [WeOaLB0102]. Presented at 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil. 2005.
5. Wilkin T, Haubrich R, Steinhart CR, Becker S, Conant M, Vangeneugden T, Spinosa-Guzman S, Godderis F, Stoffels P, Parys W. TMC114/r Superior to Standard of care in 3-Class-Experienced Patients: 24-wk Primary Analysis of the POWER 2 study (TMC114-C202) [2860]. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC. 2005.
6. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JMAH, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK, 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004 292 : 191 201.
7. Squires K, Pozniak AL, Pierone G Jr., Steinhart CR, Berger D, Bellos NC, Becker SL, Wulfsohn M, Miller MD, Toole JJ, Coakley DF, Cheng A, Study 907 Team. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003 139 : 313 20.
8. Viread™ [Tenofovir Disoproxil Fumarate]. Prescribing Information. Foster City, CA : Gilead Sciences 2004.
9. Bouche MP, Michielsen L, Piot M, Timmerman P. Swift and Simultaneous Determination of Darunavir (TMC114) and Ritonavir in Human Plasma Using LC-MS/MS [Tup-042]. Presented at: 17th International Mass Spectrometry Conference, Prague, Czech Republic. 2006.
10. Reyataz™ [Atazanavir]. Prescribing Information. Princeton, NJ : Bristol-Myers Squibb 2004.
11. Boffito M, Back D, Stainsby-Tron M, Hill A, Di Perri G, Moyle G, Nelson M, Tomkins J, Gazzard B, Pozniak A. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. Br J Clin Pharmacol 2005 59 : 38 42.
12. Zong J, Chittick G, Blum MR, Hill D, Begley J, Adda N, Shah J, Kearney BP. Pharmacokinetic Assessment of Tenofovir Disoproxil Fumarate and Ritonavir-Boosted Saquinavir in Healthy Subjects [A-444]. Presented at 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC. 2004.
13. Wilkins E. Pharmacokinetics of Telzir (fosamprenavir). J HIV Ther 2004 9 : 87 91.
14. ® [Lopinavir/ritonavir]. Prescribing Information. Chicago, IL : Abbott Laboratories 2005.
15. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004 43 : 595 612.
16. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 1999 36 : 127 43.
17. Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucl Acids 2001 20 : 641 8.
18. Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999 56 : 383 9.
19. Grinsztejn B, Arasteh K, Clotet B, Cunha CA, Goffard JC, Spinosa Guzman S, Hill A, Molina JM, Tanski C, Walgraeve H. TMC114/r Well Tolerated in 3-Class-Experienced Patients: Week 24 Primary Analysis of POWER 1 (TMC114-C213) [WePeLB6.201]. Presented at: 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil. 2005.
20. Berger D, Bellos N, Farthing C, Stryker R, Colson A, Pierone G, Lefebvre E, Cefalone M, Koester A, Van Baelen K, De Pauw M. TMC114/r in 3-Class-Experienced Patients 24-wk Primary Safety Analysis of the POWER 2 Study (C202) [H-1094]. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy,Washington DC. 2005.
21. Molina J-M, Cohen C, Katlama C, Grinsztejn B, Timerman A, Pedro R, De Meyer S, de Bethune M-P, Vangeneugden T, Lefebvre E. POWER 3 Trial: 24-Week Efficacy and Safety Results of TMC114/r in Treatment-Experienced HIV Patients [P4]. Presented at: 12th Annual Conference of the British HIV Association (BHIVA), Brighton, UK. 2006.
22. Cihlar T, Bleasby K, Pritchard J. Antiviral Acyclic Nucleotide Analogs (ANAs) Tenofovir and Adefovir are Substrates for Human Kidney Organic Anion, but not Cation Transporters: Implications for Potential Renal Drug Interactions [A-443]. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC. 2004.
23. Ray AS, Cihlar T, Robinson KL. Mechanism of Active Tubular Secretion of Tenofovir and Potential for a Renal Drug-Drug Interaction with HIV Protease Inhibitors [A-39]. Presented at: 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, Portugal. 2006.
24. Sekar V, DeMeyer S, Vangeneugden T, Lefebvre E, De Pauw M, Van Baelen B, De Paepe E, de Bethune M-P, Hoetelmans R, Parys W. Pharmacokinetic/ Pharmacodynamic (PK/PD) Analyses of TMC114 in the POWER 1 and POWER 2 Trials in Treatment-Experienced HIV-Infected Patients [J-121]. Presented at: 13th Conference on Retroviruses and Opportunistic Infections, Denver. 2006.